JP2002514180A - マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 - Google Patents

マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法

Info

Publication number
JP2002514180A
JP2002514180A JP51281898A JP51281898A JP2002514180A JP 2002514180 A JP2002514180 A JP 2002514180A JP 51281898 A JP51281898 A JP 51281898A JP 51281898 A JP51281898 A JP 51281898A JP 2002514180 A JP2002514180 A JP 2002514180A
Authority
JP
Japan
Prior art keywords
dibenzofuran
sulfonylamino
acid
phenyl
hexanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP51281898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514180A5 (cg-RX-API-DMAC10.html
Inventor
ピカード,ジョウゼフ・アーマンド
スリスコーヴィク,ドラーゴウ・ロバート
Original Assignee
ワーナー―ランバート・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー―ランバート・コンパニー filed Critical ワーナー―ランバート・コンパニー
Publication of JP2002514180A publication Critical patent/JP2002514180A/ja
Publication of JP2002514180A5 publication Critical patent/JP2002514180A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP51281898A 1996-09-04 1997-09-02 マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 Abandoned JP2002514180A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2506396P 1996-09-04 1996-09-04
US5571497P 1997-08-07 1997-08-07
US60/025,063 1997-08-07
US60/055,714 1997-08-07
PCT/US1997/015444 WO1998009957A1 (en) 1996-09-04 1997-09-02 Compounds for and a method of inhibiting matrix metalloproteinases

Publications (2)

Publication Number Publication Date
JP2002514180A true JP2002514180A (ja) 2002-05-14
JP2002514180A5 JP2002514180A5 (cg-RX-API-DMAC10.html) 2005-04-07

Family

ID=26699217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51281898A Abandoned JP2002514180A (ja) 1996-09-04 1997-09-02 マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法

Country Status (10)

Country Link
US (1) US6294674B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929542A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514180A (cg-RX-API-DMAC10.html)
KR (1) KR20000068415A (cg-RX-API-DMAC10.html)
AU (1) AU736347B2 (cg-RX-API-DMAC10.html)
BR (1) BR9712794A (cg-RX-API-DMAC10.html)
CA (1) CA2256631A1 (cg-RX-API-DMAC10.html)
HR (1) HRP970474B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ333064A (cg-RX-API-DMAC10.html)
WO (1) WO1998009957A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073719A1 (ja) * 2008-12-26 2010-07-01 国立大学法人京都大学 Eg5阻害剤
JP2019507130A (ja) * 2016-02-01 2019-03-14 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. ベンゾピラゾール化合物及びその類似体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
US6350885B1 (en) 1998-07-30 2002-02-26 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
CN1229339C (zh) * 2000-03-27 2005-11-30 斯克里普斯研究学院 抑制血管生成和肿瘤生长的化合物,含有该化合物的药用制剂,以及该化合物的制药用途
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CN1318411C (zh) * 2005-03-21 2007-05-30 中国海洋大学 氢化轮枝霉酮类化合物及其制备方法和用途
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
EP2074107A2 (en) * 2006-10-27 2009-07-01 Wyeth a Corporation of the State of Delaware Tricyclic compounds as matrix metalloproteinase inhibitors
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
CA2692004C (en) * 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
WO2021147882A1 (zh) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2065966C3 (de) 1969-09-06 1978-11-16 Ajinomoto Co., Inc., Tokio N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel
US3845097A (en) 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
US4097472A (en) 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
DE2236876C3 (de) * 1971-08-19 1981-02-12 Ajinomoto Co., Inc., Tokio N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
EP0183271B1 (en) * 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5627206A (en) 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5665764A (en) 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
DK0828726T3 (da) 1995-06-02 2002-01-21 Warner Lambert Co Tricykliske inhibitorer af matrixmetalloproteinaser
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
NZ333063A (en) 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073719A1 (ja) * 2008-12-26 2010-07-01 国立大学法人京都大学 Eg5阻害剤
JP2019507130A (ja) * 2016-02-01 2019-03-14 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. ベンゾピラゾール化合物及びその類似体

Also Published As

Publication number Publication date
US6294674B1 (en) 2001-09-25
WO1998009957A1 (en) 1998-03-12
EP0929542A1 (en) 1999-07-21
KR20000068415A (ko) 2000-11-25
BR9712794A (pt) 1999-12-14
CA2256631A1 (en) 1998-03-12
AU736347B2 (en) 2001-07-26
HRP970474A2 (en) 1998-12-31
HRP970474B1 (en) 2002-10-31
NZ333064A (en) 2000-11-24
AU4177097A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
US6294674B1 (en) Dibenzofuran sulfonamide matrix metalloproteinase inhibitors
KR100352316B1 (ko) 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
US6117869A (en) Compounds for and methods of inhibiting matrix metalloproteinases
EP0960108B1 (en) Matrix metalloproteinase inhibitors
AU735013B2 (en) Matrix metalloproteinase inhibitors and their therapeutic uses
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
KR20000035925A (ko) 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드
EP0586537A1 (en) Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
MXPA98001093A (en) Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag
JP2000511175A (ja) ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤
JPH08503475A (ja) 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
CZ195298A3 (cs) Aromatické keto-kyseliny a jejich deriváty jako inhibitory matricových metaloproteináz
US5679700A (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
JPH04210966A (ja) 新規化合物、その製法及びそれを含む医薬組成物
WO1994007481A1 (en) N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
PT828726E (pt) Inibidores triciclicos de metaloproteinases de matriz
US6624177B1 (en) Matrix metalloproteinase inhibitors and their therapeutic uses
US6090785A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
ZA200103605B (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases.
EP0723974A1 (fr) Dérivés de mercaptoalcanoyldipeptides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MXPA98009929A (en) Compounds for and a method of inhibiting matrix metalloproteinases
US5932551A (en) Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative active agents
JP2006500422A (ja) 酵素活性を阻害するためのキレート化剤の親油性ジエステル
MXPA98009871A (en) Matrix metalloproteinase inhibitors and their therapeutic uses
FR2973374A1 (fr) Nouveaux alkylthioethers, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040819

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20060306

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20060306